Atossa Genetics (NASDAQ: ATOS) and Alliqua Biomedical (NASDAQ:ALQA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Risk and Volatility

Atossa Genetics has a beta of 3.22, indicating that its stock price is 222% more volatile than the S&P 500. Comparatively, Alliqua Biomedical has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Institutional and Insider Ownership

51.9% of Atossa Genetics shares are owned by institutional investors. Comparatively, 16.5% of Alliqua Biomedical shares are owned by institutional investors. 3.1% of Atossa Genetics shares are owned by insiders. Comparatively, 13.2% of Alliqua Biomedical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Atossa Genetics and Alliqua Biomedical’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Atossa Genetics N/A N/A -$8.12 million N/A N/A
Alliqua Biomedical $19.57 million 0.52 -$25.70 million ($6.49) -0.31

Atossa Genetics has higher earnings, but lower revenue than Alliqua Biomedical.


This table compares Atossa Genetics and Alliqua Biomedical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atossa Genetics N/A -186.36% -145.47%
Alliqua Biomedical -114.41% -122.50% -63.67%

Analyst Ratings

This is a breakdown of current recommendations for Atossa Genetics and Alliqua Biomedical, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atossa Genetics 0 0 2 0 3.00
Alliqua Biomedical 0 1 0 0 2.00

Atossa Genetics presently has a consensus price target of $10.00, suggesting a potential upside of 360.83%. Alliqua Biomedical has a consensus price target of $2.80, suggesting a potential upside of 37.93%. Given Atossa Genetics’ stronger consensus rating and higher possible upside, research analysts plainly believe Atossa Genetics is more favorable than Alliqua Biomedical.


Atossa Genetics beats Alliqua Biomedical on 7 of the 11 factors compared between the two stocks.

Atossa Genetics Company Profile

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.

Alliqua Biomedical Company Profile

Alliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies. It also provides contract manufacturing services, including the development, manufacture, and marketing of high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company is headquartered in Yardley, Pennsylvania.

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with's FREE daily email newsletter.